Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19497727 | 0.85 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL1470095 | 0.78 | — | — | |
| SCHEMBL19504334 | 0.78 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL19504327 | 0.76 | — | — | |
| SCHEMBL20441261 | 0.76 | — | — | |
| SCHEMBL19509634 | 0.76 | — | — | |
| SCHEMBL11914091 | 0.73 | — | — | |
| SCHEMBL14238583 | 0.73 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL19833142 | 0.73 | — | — | |
| SCHEMBL19497730 | 0.73 | TSHR (0.35) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| WO-2020201080-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA AB (SE) | 2020-10-08 | — | — | WO | disclosed |
| EP-3689873-A1 | ESTROGEN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2020-08-05 | — | — | EP | disclosed |
| EP-3640251-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| WO-2018138303-A1 | ESTROGEN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
| WO-2018019793-A1 | N-(2-(4-((1R,3R)-3-METHYL-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PHENOXY)ETHYL)PROPAN-1-AMINE DERIVATIVES AND RELATED COMPOUNDS AS SELECTIVE DOWN-REGULATORS OF THE ESTROGEN RECEPTOR FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2018-02-01 | — | — | WO | disclosed |
| US-20170305909-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2017182493-A1 | INDAZOLE DERIVATIVES FOR USE IN DOWN-REGULATION OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305909-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TSHR 3354/4885TDP1 3073/4885 |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TSHR 3246/4885TDP1 3081/4885 |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TSHR 3246/4885TDP1 3081/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | TSHR 687/4885TDP1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.